Literature DB >> 19465940

Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

E Peres1, J E Levine, Y A Khaled, R B Ibrahim, T M Braun, O I Krijanovski, S Mineishi, M H Abidi.   

Abstract

Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complications in 278 recipients of RIC from July 2000 to July 2006. All patients received conditioning with BU, fludarabine and TBI. Patients were evaluated from conditioning therapy until 100 days after HSCT. Median age was 56 years. Cardiac events were defined as either one or more of the following: arrhythmias, myocardial infarction or congestive heart failure. Twenty-five patients developed arrhythmias at a median of 3 days post transplant, in 19 patients hemodynamic compromise occurred and mechanical ventilation was required in 15 patients. The arrhythmias included atrial fibrillation (n=17), atrial flutter (n=6) and supraventricular tachycardia (n=2). Troponin was elevated in 12 out of 25 patients. The mean brain natriuretic peptide was 679. All patients converted to a normal rhythm by medical therapy at a median of 2 days. Recurrence of arrhythmia occurred in 76% of patients. Day 100 mortality was 40% in this group. A history of high-dose anthracycline treatment and a low ejection fraction were risk factors for the development of cardiac complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465940      PMCID: PMC3796338          DOI: 10.1038/bmt.2009.97

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  31 in total

Review 1.  Haemopoietic stem-cell transplantation: recent progress and future promise.

Authors:  C Craddock
Journal:  Lancet Oncol       Date:  2000-12       Impact factor: 41.316

2.  Acute left ventricular failure following melphalan and fludarabine conditioning.

Authors:  D S Ritchie; J F Seymour; A W Roberts; J Szer; A P Grigg
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

3.  Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.

Authors:  K Fujimaki; A Maruta; M Yoshida; R Sakai; J Tanabe; H Koharazawa; F Kodama; S Asahina; M Minamizawa; M Matsuzaki; S Fujisawa; H Kanamori; Y Ishigatsubo
Journal:  Bone Marrow Transplant       Date:  2001-02       Impact factor: 5.483

4.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

5.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Authors:  S Giralt; P F Thall; I Khouri; X Wang; I Braunschweig; C Ippolitti; D Claxton; M Donato; J Bruton; A Cohen; M Davis; B S Andersson; P Anderlini; J Gajewski; S Kornblau; M Andreeff; D Przepiorka; N T Ueno; J Molldrem; R Champlin
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

6.  Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.

Authors:  B E Brockstein; C Smiley; J Al-Sadir; S F Williams
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

7.  Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

Authors:  R Martino; M D Caballero; C Canals; J A Simón; C Solano; A Urbano-Ispízua; J Bargay; C Rayón; A Léon; J Sarrá; J Odriozola; J G Conde; J Sierra; J San Miguel
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

Review 8.  Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Authors:  L C M Kremer; H J H van der Pal; M Offringa; E C van Dalen; P A Voûte
Journal:  Ann Oncol       Date:  2002-06       Impact factor: 32.976

9.  Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.

Authors:  B V Jensen; T Skovsgaard; S L Nielsen
Journal:  Ann Oncol       Date:  2002-05       Impact factor: 32.976

10.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

View more
  13 in total

1.  Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT.

Authors:  K P Daly; S D Colan; E D Blume; R Margossian; K Gauvreau; C Duncan; L E Lehmann; M H Chen
Journal:  Bone Marrow Transplant       Date:  2011-01-31       Impact factor: 5.483

Review 2.  Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.

Authors:  Federico Viganego; Robin Singh; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

3.  The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution.

Authors:  M Arun; D Brauneis; G Doros; A C Shelton; J M Sloan; K Quillen; F L Ruberg; V Sanchorawala; C Varga
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

4.  The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation.

Authors:  Małgorzata Poręba; Paweł Gać; Lidia Usnarska-Zubkiewicz; Witold Pilecki; Kazimierz Kuliczkowski; Grzegorz Mazur; Małgorzata Sobieszczańska; Rafał Poręba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-01-24       Impact factor: 1.468

5.  Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

Authors:  Abhishek Singla; William J Hogan; Stephen M Ansell; Francis K Buadi; David Dingli; Angela Dispenzieri; Dennis A Gastineau; Morie A Gertz; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Martha Q Lacy; Mark R Litzow; Ivana N Micallef; Luis F Porrata; Shaji K Kumar
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-06       Impact factor: 5.742

6.  Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?

Authors:  Peter Hurley; Suma Konety; Qing Cao; Daniel Weisdorf; Anne Blaes
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-16       Impact factor: 5.742

Review 7.  Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training.

Authors:  Jessica M Scott; Saro Armenian; Sergio Giralt; Javid Moslehi; Thomas Wang; Lee W Jones
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-17       Impact factor: 6.312

Review 8.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

Review 9.  Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT).

Authors:  Teresa López-Fernández; Irene Sánchez Vadillo; Ana López de la Guía; Karem Humala Barbier
Journal:  Curr Treat Options Oncol       Date:  2021-04-30

10.  Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Lubica Roziakova; Eva Bojtarova; Martin Mistrik; Juraj Dubrava; Jozef Gergel; Nadezda Lenkova; Beata Mladosievicova
Journal:  J Exp Clin Cancer Res       Date:  2012-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.